iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Core Insights - iBio, Inc. announced promising preclinical data for its Activin E antibody candidate, IBIO-610, showing a reduction of 6.7% in visceral fat and 5.2% in total fat mass in obese non-human primates despite a high-calorie diet [1][2][3] Group 1: Study Findings - The preclinical study demonstrated that IBIO-610 significantly reduced fat mass in obese non-human primates compared to vehicle-treated controls, although the study was small and not statistically powered [2] - Following two doses administered every eight weeks, the treatment resulted in a slight increase in lean mass, indicating a fat-selective profile consistent with previous rodent studies and human clinical trials targeting the Activin E pathway [2][4] Group 2: Therapeutic Potential - The results support the continued evaluation of IBIO-610 as a differentiated therapy for obesity, cardiometabolic, and cardiopulmonary diseases, with the potential to improve patient outcomes [2][3] - iBio's CEO highlighted the extended half-life of IBIO-610, reported at 33.2 days in non-human primates and projected to be up to 100 days in humans, suggesting the possibility of convenient dosing schedules [3] Group 3: Company Overview - iBio, Inc. is a biotech company focused on developing next-generation biopharmaceuticals for challenging diseases, leveraging AI and advanced computational biology to create innovative therapies [5] - The company aims to transform drug discovery and accelerate development timelines, addressing significant unmet medical needs in the fields of cardiometabolic, obesity, and cardiopulmonary diseases [5]